iQor CXBPO™ Unveils infinityAiQ™ Platform Powering the Future of Intelligent Customer Experiences
Unified Intelligence Platform Integrates AI, Analytics, and Expertise to Drive Business Performance
FT. LAUDERDALE, Fla., June 05, 2025 (GLOBE NEWSWIRE) -- iQor CXBPO™, an award-winning customer experience business process outsourcing (BPO) provider, today announced the launch of infinityAiQ™, a unified intelligence platform that combines human expertise, AI, and analytics to optimize every stage of the customer experience. The platform is designed to help clients deepen loyalty, reduce costs, and increase revenue through smarter, more adaptive CX operations.
Built to power iQor's CXBPO model, the infinityAiQ platform integrates intelligence across the agent and customer lifecycles — from hiring and training to engagement, resolution, and recovery. It combines secure infrastructure, proprietary AI tools, and enriched data pipelines into a cohesive, scalable system. A key component, Insights iQ™, extracts predictive, real-time intelligence from every customer interaction. Powered by iQor's VALDI advanced analytics engine and enhanced through an industry-first collaboration with OpenAI, Insights iQ enables brands to act on 100% of conversations — not just samples — to uncover trends, detect churn risks, and accelerate action.
'infinityAiQ is the engine propelling our CXBPO model to help clients compete in a world where customer experience drives business growth,' said iQor President and CEO Chris Crowley. 'By harnessing data, technology, and expertise, we deliver a scalable foundation for faster innovation, smarter decisions, and stronger customer relationships. This platform enables our clients to move beyond traditional outsourcing models and into proactive, insight-driven growth.'
infinityAiQ offers three integrated solution pillars to help brands turn customer experience into competitive advantage:
People iQ: Intelligent hiring, onboarding, and training systems that match best-fit talent to client needs, building high-performing, scalable teams.
Process iQ: Streamlined workflows and automation that reduce costs and improve speed, accuracy, and customer satisfaction.
Insights iQ: Predictive analytics and real-time decisioning tools that identify patterns, uncover opportunities, and drive revenue-enhancing CX strategies.
iQor's investment in automation and machine learning enables its infinityAiQ platform to process over 2.7 billion tokens per week through LLMs and apply advanced predictive analytics to 100% of the call volume, driving significant improvements in performance and customer experience.
'infinityAiQ is the culmination of years of investment in secure infrastructure, proprietary AI, and advanced analytics,' said Prabhjot Singh, Chief Digital Officer at iQor. 'We've engineered a platform that transforms unstructured data from every interaction into real-time business intelligence — fueling predictive decisioning, automation, and continuous optimization across the CX journey.'
With iQor's PCI-DSS, SOC 1 and 2 Type 2, HITRUST, and ISO 27001 certifications, as well as HIPAA compliance, infinityAiQ provides clients with the confidence of operating on a secure, resilient infrastructure. Whether deployed as a full contact center solution or integrated with existing systems, the platform is designed to deliver unmatched intelligence and flexibility across omnichannel environments without disruption.
To learn more about how infinityAiQ powers unified intelligence for unmatched CX results, visit www.iqor.com/infinityAiQ.
About iQor CXBPO™iQor CXBPO™ is a trusted partner in intelligent customer experience solutions, delivering exceptional results for global brands. With 40,000 employees across 10 countries, we combine 30 years of industry expertise with cutting-edge AI-driven innovations to optimize customer interactions at every stage. Our agile, scalable solutions ensure seamless omnichannel engagement, driving loyalty and measurable business success. Recognized as a Great Place to Work® and a leader in CX excellence, we elevate performance through a people-first approach, operational expertise, and secure, technology-enabled solutions. Learn more at iQor.com.
CONTACT: iQor Global Contact Nicole Gobbo Director of Communications nicole.gobbo@iqor.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
43 minutes ago
- Yahoo
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 06, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on June 2, 2025 (the 'Grant Date'), ORIC granted a total of 39,100 non-qualified stock options and 6,500 restricted stock units to three new non-executive employees who began their employment with ORIC in May 2025. These inducement grants were granted pursuant to the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan, subject to recipient's continued employment or service through each applicable vesting date. The stock options have an exercise price equal to the closing price of ORIC's common stock on the Grant Date. Twenty-five percent (25%) of the shares subject to the stock options will vest on the one (1) year anniversary of the Grant Date, with one thirty-sixth (1/36th) of the remaining shares vesting each one-month period thereafter. One-third (1/3rd) of the restricted stock units will vest on each of the first three anniversaries of the Grant Date. The inducement grants are subject to the terms and conditions of the applicable stock option and restricted stock unit agreements and the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan. The inducement grants were approved by ORIC's Compensation Committee of the Board of Directors, as required by Nasdaq Rule 5635(c)(4), and were granted as a material inducement to employment in accordance with Nasdaq Rule 5635(c)(4). About ORIC Pharmaceuticals, Inc. ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients' lives by Overcoming Resistance In Cancer. ORIC's clinical stage product candidates include (1) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (2) ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. Beyond these two product candidates, ORIC® is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to and follow us on X or LinkedIn. Cautionary Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, statements regarding the vesting of the inducement grants; target indications for ORIC's product candidates; the potential advantages of ORIC's product candidates; and plans underlying ORIC's clinical trials and development. Words such as 'believes,' 'anticipates,' 'plans,' 'expects,' 'intends,' 'will,' 'goal,' 'potential' and similar expressions are intended to identify forward-looking statements. The forward-looking statements contained herein are based upon ORIC's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those projected in any forward-looking statements due to numerous risks and uncertainties, including but not limited to: risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics and operating as an early clinical stage company; ORIC's ability to develop, initiate or complete preclinical studies and clinical trials for, obtain approvals for and commercialize any of its product candidates; changes in ORIC's plans to develop and commercialize its product candidates; the potential for clinical trials of ORIC's product candidates to differ from preclinical, initial, interim, preliminary or expected results; negative impacts of health emergencies, economic instability or international conflicts on ORIC's operations, including clinical trials; the risk of the occurrence of any event, change or other circumstance that could give rise to the termination of ORIC's license and collaboration agreements; the potential market for our product candidates, and the progress and success of competing therapeutics currently available or in development; ORIC's ability to raise any additional funding it will need to continue to pursue its business and product development plans; regulatory developments in the United States and foreign countries; ORIC's reliance on third parties, including contract manufacturers and contract research organizations; ORIC's ability to obtain and maintain intellectual property protection for its product candidates; the loss of key scientific or management personnel; competition in the industry in which ORIC operates; general economic and market conditions; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled 'Risk Factors' in ORIC's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the 'SEC') on May 5, 2025, and ORIC's future reports to be filed with the SEC. These forward-looking statements are made as of the date of this press release, and ORIC assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Contact:Dominic Piscitelli, Chief Financial info@ sesión para acceder a tu cartera de valores
Yahoo
an hour ago
- Yahoo
PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025
PETACH TIKVA, Israel, June 06, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), ('PolyPid' or the 'Company'), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will host a conference call and webcast to report topline data for the SHIELD II Phase 3 trial, evaluating D-PLEX100 for the prevention of surgical site infections in patients undergoing abdominal colorectal surgery, on Monday, June 9, at 8:30 a.m. ET. To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. Conference Call Dial-In & Webcast Information: Date: Monday, June 9, 2025 Time: 8:30 AM Eastern Time Conference Call: Webcast: About PolyPid PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid's proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid's lead product candidate D-PLEX100 is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning with glioblastoma. For additional Company information, please visit and follow us on Twitter and LinkedIn. Contacts:PolyPid Ltd. Ori WarshavskyCOO – US908-858-5995IR@ Investors:Brian RitchieLifeSci Advisors212-915-2578britchie@
Yahoo
an hour ago
- Yahoo
AYR Announces Entry into Limited Waiver Agreement with Senior Noteholders
MIAMI, June 06, 2025 (GLOBE NEWSWIRE) -- AYR Wellness Inc. (CSE: AYR.A, OTCQX: AYRWF) ('AYR' or the 'Company'), a leading vertically integrated U.S. multi-state cannabis operator, announces that it has entered into a Limited Waiver Agreement (the 'Agreement') with the holders of a majority of its senior secured notes (the 'Majority Holders'). The Agreement provides a temporary waiver of certain events of default under the Company's senior note documents, including those arising from the Company's previously announced delay in filing its interim financial statements for the quarter ended March 31, 2025, and certain payment defaults under other outstanding debt obligations (including certain of the Company's unsecured and/or subordinated debt obligations) should the Company determine not to make such payments when due. The waiver is effective through June 19, 2025, unless terminated earlier upon the occurrence of certain specified events, including a termination event of default should the Company make any payments otherwise due under its unsecured and/or subordinated debt obligations. The Company is actively engaged in ongoing negotiations with its senior lenders and continues to assess strategic alternatives to address its capital structure and upcoming payment obligations. The entry into the Agreement provides the Company with additional time and flexibility to continue these discussions and pursue its strategic objectives. The Agreement temporarily restricts the Majority Holders from exercising their default-related rights and remedies with respect to the specified defaults during the waiver period, subject to the terms and conditions set forth in the Agreement. The Agreement does not constitute a permanent waiver of any defaults or a waiver of any other rights or remedies under the senior note documents. AYR remains committed to operating its business in the ordinary course and to delivering high-quality cannabis products to its patients and customers. The Company will continue to provide updates regarding the status of the Agreement and any material developments as they arise. Forward-Looking StatementsCertain statements contained in this news release may contain forward-looking information or may be forward-looking statements (collectively, 'forward-looking statements') within the meaning of applicable securities laws. Forward-looking statements are often, but not always, identified by the use of words such as 'target', 'expect', 'anticipate', 'believe', 'foresee', 'could', 'would', 'estimate', 'goal', 'outlook', 'intend', 'plan', 'seek', 'will', 'may', 'tracking', 'pacing' and 'should' and similar expressions or words suggesting future outcomes. This news release includes forward-looking statements pertaining to, among other things, the entry into the Agreement, the Company's ongoing negotiations with its senior lenders, the outcome of the strategic review process and the Company's ability to continue to operate in the ordinary course. Numerous risks and uncertainties could cause actual events and results to differ materially from the estimates, beliefs and assumptions expressed or implied in the forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties that may cause actual results to differ materially from those anticipated. AYR has no intention, and undertakes no obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. About AYR Wellness Wellness is a vertically integrated, U.S. multi-state cannabis business. The Company operates simultaneously as a retailer with 90+ licensed dispensaries and a house of cannabis CPG brands. AYR is committed to delivering high-quality cannabis products to its patients and customers while acting as a Force for Good for its team members and the communities that the Company serves. For more information, please visit Company/Media Contact:Robert VaniskoSVP, Public AffairsT: (786) 885-0397Email: comms@ Investor Relations Contact:Sean Mansouri, CFAElevate IRT: (786) 885-0397
